Company / PP&E (Net)
Celldex Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$5.3M
FY2025
5-year range
$3.6M / $5.3M
FY2021-FY2025
Trend
+22.7%
vs FY2024
Sector context
#131 of 138
Health Care
What the data says
Among 138 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 5% for pp&e (net). PP&E (Net) has increased for 4 consecutive years, from $4M in FY2021 to $5M in FY2025.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of +6.9%.
Improved from $4M to $5M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +12.5%
- 5-Year CAGR
- +6.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 138This company $5.3M Sector average $1.4B
▼
-99.6% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s pp&e (net) has grown for 4 consecutive years.
- 5-year CAGR of +6.9%, indicating consistent growth.
- In FY2025, pp&e (net) increased 22.7% year-over-year.
- Ranks #131 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.3M | +22.7% |
| FY2024 | $4.3M | +7.0% |
| FY2023 | $4.1M | +8.4% |
| FY2022 | $3.7M | +5.5% |
| FY2021 | $3.6M | -6.9% |
| FY2020 | $3.8M | -5.4% |
| FY2019 | $4.0M | -34.0% |
| FY2018 | $6.1M | -41.1% |
| FY2017 | $10.4M | -21.4% |
| FY2016 | $13.2M | +15.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026